| From: Paul H. Christiansen | 2/12/2020 10:06:49 AM | | | | | | Preparing for a Digital Transformation in Manufacturing
Most CEOs understand they are in a race to implement artificial intelligence
Last year, the Association for Advancing Automation (A3) surveyed our members about their companies’ adoption of AI. More than 76% of respondents felt that AI will be important to their companies in the next 3 years. However, just 3.3% of those surveyed said that AI was being widely applied in their organizations.
This has been called the Ambition-Execution Gap.
Companies know they need to implement AI strategies but are frequently at a loss on where to begin. Or they get stuck in a pilot purgatory where AI initiatives never reach a scale where they can help the overall enterprise. Even when on the right track, there’s not the talent in the pipeline to support their efforts.
Read More – Association for Advancing Automation |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/13/2020 3:26:49 PM | | | | | | PolarityTE Announces Pricing of Public Offering of Common Stock and Warrants
Has the subsequent selloff been irrational?
On Tuesday of this week PTE made the above announcement after the market closed. On Wednesday, PTE opened at $1.75 per share, down 45% from the previous day’s close. For the day, more than 7 million shares traded, almost all within a small variance of $1.70 per share.
The sell-off was probably expected: traditional Wall Street thinking dictates that investors should sell whenever existing shares are exposed to dilution.
However, one has to wonder if those selling their shares bothered to read the following - Our Vision – which is taken verbatim from a separate registration statement filed with the SEC and which will be included in the final Prospectus.
The section Where You Can Find More Information offers instructions on how to obtain that information.
Here is PTE’s Our Vision:
We aspire to be a global biotechnology company that provides superior, tangible, and pragmatic platform technologies that provide superior results to patients, while reducing costs and promoting improved health economics for patients, providers, and payors. We believe this can be accomplished through our pursuit of complex simplicity, which embodies the development of robust cell/tissue-derived therapies that can be efficiently produced and deployed. PolarityTE is committed to delivering transformative technology that positively impacts humanity.
PolarityTE was founded by a dedicated group of doctors and scientists from The Johns Hopkins University School of Medicine, who left to become part of something bigger. Something that could transform the future of medicine. We believe that living systems require more than a simple singular input (for example a growth factor, stem cell, or nano-particle), to produce a complex output. Therefore, we took a different direction and developed multi-tiered platform technologies that propagate the necessary complex substrate required for regenerating fully-functional tissue, such as skin, bone, cartilage, muscle, blood vessels, and neural elements, as well as solid and hollow organ composite tissue systems. We have engineered and developed our regenerative materials and core tissue substrate technology platforms to allow us to induce, maintain, and promote the integrated polarity, organized assembly, and interface development of cells and tissues, so that they replicate regenerative healing in the body and are not seen as foreign by the immune system.
The core technology of TE products is minimally polarized functional units (“MPFUs”) consisting of self-complexing intelligent regenerative materials (“SCIRM”). SCIRM within an MPFU form polarizing, multi-cellular aggregates that act as an intrinsic, regenerative bio-reactor capable of expanding, proliferating, and synthesizing cells, materials, factors, or systems necessary for regenerating full-thickness, three-dimensional tissue. The TE products we develop begin with the patient’s own tissue to produce SCIRM that address the specific tissue or system needed for the patient’s care. Our product pipeline focuses on the development of regenerative products for a variety of tissue types and organ systems that are commonly altered, injured, or destroyed by a variety of diseases, pathologies, traumatic events, and medical interventions.
SkinTE, our first tissue product, was registered with the United States Food and Drug Administration (FDA) in August 2017, and is now commercially available for the repair, reconstruction, replacement, and regeneration of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. We are pursuing a regional plan for commercial rollout that began in late October 2018, and at the beginning of January 2019 we had 24 sales representatives in the field marketing SkinTE.
OsteoTE is designed to utilize the patient’s bone to repair, reconstruct, replace, supplement, or regenerate bone damage or defects. We registered OsteoTE with the FDA in December 2018. We are preparing for the first application of the product in a clinical setting, which we are endeavoring to achieve in the first half of 2019.
Human cells, tissues and cellular and tissue-based products (“HCT/Ps”) are governed by specific FDA regulations that provide for a registration pathway that is different than the pathway for traditional drug candidates. SkinTE and OsteoTE are both registered as HCT/Ps under Section 361 of the Public Health Service Act.
We have a number of additional TE products under development, including the following:
· AdipoTE to optimize the delivery of autologous fat beyond the capabilities of current fat transfer techniques utilized in procedures on, among others, the breast, buttocks, and face;
· AngioTE to address vascular regeneration including microscopic capillary networks all the way up to great vessel replacement;
· NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures;
· UroTE targeting the delivery of autologous urogenital epithelium and submucosa across a spectrum of diseases and processes, including urethral strictures, urethral creation, bladder reconstruction, and ureter reconstruction;
· LiverTE to address numerous causes of liver failure, including NASH, fibrosis/cirrhosis, surgical resection of the liver; and
· BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue.
RTD and ARC represent research and development of new science and product opportunities based on what we learned while developing the TE platform. RTD is focused on altered state analytes for the generation of composite materials that can be utilized for the augmentation, modulation, and regulation of cell and tissue-derived systems. ARC is focused on the design and development of gene transfer, small molecule synthesis, composite therapeutics, and alteration of self-propagating cell/tissue-derived bioreactors.
We have significant research facilities and a well-educated and skilled team of scientists and researchers. These resources are highly beneficial to the work we are doing on our TE products and in RTD and ARC. We also offer research services to unrelated third parties on a contract basis, which we offer under the trademark POLARITYRD. Contract research services help us defray the costs of maintaining a first-rate research facility and allow us to meet companies pursuing new technologies that may be opportunities for collaborative or strategic relationships going forward. |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/14/2020 12:13:53 PM | | | | | | Crispr'd Cells Show Promise in First US Human Safety Trial
It’s been over three years since US regulators greenlit the nation’s first in-human test of Crispr’s disease-fighting potential, more than three years of waiting to find out if the much-hyped gene-editing technique could be safely used to beat back tough-to-treat cancers. Today, researchers from the University of Pennsylvania and Stanford finally revealed the first published report describing the trial. The highly anticipated results showed that the procedure is both safe and feasible; the Crispr’d cells went where they were supposed to go and survived for longer than expected. They didn’t cure anyone’s cancer, but they didn’t kill anyone, either, which means the results hold significant promise for the future of Crispr-based medicines.
Read More - Wired |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/18/2020 9:05:35 AM | | | | | | The messy, secretive reality behind OpenAI’s bid to save the world
The AI moonshot was founded in the spirit of transparency. This is the inside story of how competitive pressure eroded that idealism.
Every year, OpenAI’s employees vote on when they believe artificial general intelligence, or AGI, will finally arrive. It’s mostly seen as a fun way to bond, and their estimates differ widely. But in a field that still debates whether human-like autonomous systems are even possible, half the lab bets it is likely to happen within 15 years.
In the four short years of its existence, OpenAI has become one of the leading AI research labs in the world. It has made a name for itself producing consistently headline-grabbing research, alongside other AI heavyweights like Alphabet’s DeepMind. It is also a darling in Silicon Valley, counting Elon Musk and legendary investor Sam Altman among its founders.
Read More - $MIT Technology Review |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/18/2020 9:26:40 AM | | | | | | The Datacenter Has an Appetite for GPU Compute
It is not inconceivable, but probably also not very likely, that the datacenter business at GPU juggernaut Nvidia could at some point in the next one, two, or three years equal that of the core and foundational gaming sector. It is hard to tell based on current trends, and it all depends on how you extrapolate the two revenue streams from their current points and slopes and reconcile that against longer term data for the past six years.
The datacenter business at Nvidia was much smaller than the company’s OEM and IP businesses only a few years ago, and on par with its automotive segment until 2017, when GPU-accelerated HPC first really took off after a decade of heavy investment by the company and also when various kinds of machine learning had matured enough to for it to go into production at many of the hyperscalers and to be deployed as a compute engine on the large public clouds. Only four years ago, HPC represented about two-thirds of the accelerated compute sales for Nvidia’s datacenter products with the remainder largely dominated by early AI systems, mostly for machine learning training but also for some inference and also for experimentation with hybrid HPC-AI workloads. Now, as fiscal 2020 comes to a close in January, we infer from what Nvidia is saying about hyperscalers that AI probably represents well north of half of the datacenter revenue stream.
Read More – The Next Platform |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/18/2020 9:31:33 AM | | | | | | Robotic process automation is a big market, but there will be only one big winner
The market for robotic process automation is one of the hottest in tech right now, rapidly gaining traction as larger enterprises look to speed up their business processes by automating mundane office tasks.
A lot of the buzz around RPA comes from the massive amounts of money being injected into the market. The two biggest players in RPA right now, Automation Anywhere Inc. and UiPath Inc., are both startups that have raised almost $1 billion between them, sharing a combined market value of nearly $14 billion. Meanwhile, the market generated revenue of around $1 billion in 2019, almost double a year ago.
Read More - siliconANGLE |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/19/2020 10:09:51 AM | | | | | | Hackers can trick a Tesla into accelerating by 50 miles per hour
Hackers have manipulated multiple Tesla cars into speeding up by 50 miles per hour. The researchers fooled the car’s Mobileye EyeQ3 camera system by subtly altering a speed limit sign on the side of a road in a way that a person driving by would almost never notice.
This demonstration from the cybersecurity firm McAfee is the latest indication that adversarial machine learning can potentially wreck autonomous driving systems, presenting a security challenge to those hoping to commercialize the technology.
Read More - $MIT Technology Review |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/19/2020 10:13:56 AM | | | | | | AI, the Transcription Economy, and the Future of Work
Gabriel is a professional transcriber, and for years he earned a middle-class living. In the early 2000s he'd make up to $40 an hour transcribing corporate earnings calls. He'd sit at his desk, “knock it out” for hours using custom keystrokes, and watch the money roll in. “I sent my son to private schools and university on transcribing,” he tells me. “It was a nice life.”
But in the past decade, the bottom fell out. As audio recordings went digital and broadband spread, clients could ship work to India and the Philippines. Meanwhile, buzzy Silicon Valley startups emerged—like Rev, a sort of Uber and 800-pound gorilla of the transcription world. It has moved the industry toward an on-demand gig model. Since Rev charged customers a flat rate of $1 per audio minute—less than half what transcription firms historically charged—Gabriel's pay sank even further. On top of it all, AI started nipping away at the industry, with machines now able to rapidly transcribe some audio as well as humans do.
Read More - $Wired |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/19/2020 10:17:08 AM | | | | | | America’s monopoly problem, explained by your internet bill
In the summer of 2017, I decided it was time to put on my big-girl pants and try to talk to my internet provider about my bill. It had been gradually ticking up over the past several months without explanation — let alone better service — and I wanted to know what was up. When I called the company’s customer service line, the woman on the phone knew something I did not: I didn’t really have other service options available in my area. So, no, my bill would not be reduced.
More than two years later, I’m still mad about it. And yes, that could seem a little petty. But that monthly annoyance speaks to a broader trend that all Americans should be aware of — and angry about. Across industry after industry, sector after sector, power and market share have been consolidated into the hands of a handful of players.
Read More - Vox |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Paul H. Christiansen | 2/19/2020 10:22:47 AM | | | | | | Carbon Capture Wins Fans Among Oil Giants
Can new technology suck carbon dioxide, a prevalent greenhouse gas, out of the air—economically? More companies are betting that it can, as governments adopt ambitious carbon-emissions targets and investors grow increasingly concerned about the risks of climate change.
Carbon-capture techniques have existed for decades. But it’s incredibly expensive—not to mention energy intensive—to remove the carbon dioxide from the atmosphere on a large enough scale to make a significant dent.
Now, Exxon Mobil Corp., Microsoft Corp. and others are focused on reducing the cost and the amount of energy required to capture carbon dioxide. Some companies are using giant fans to suck up air, then separating the carbon dioxide chemically. One venture plans to fill land in Arizona with dozens of accordionlike machines designed to expand as they absorb the gas.
Read More $WSJ |
| | Investing in Exponential Growth | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
